Amphastar Pharmaceuticals (AMPH)
(Delayed Data from NSDQ)
$42.46 USD
-0.20 (-0.47%)
Updated May 3, 2024 04:00 PM ET
After-Market: $42.47 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth F Momentum C VGM
Price, Consensus and EPS Surprise
AMPH 42.46 -0.20(-0.47%)
Will AMPH be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for AMPH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AMPH
Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q1 Earnings? What You Should Know
Amphastar Pharmaceuticals (AMPH) Reports Next Week: Wall Street Expects Earnings Growth
AMPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Amphastar (AMPH) Could Beat Earnings Estimates Again
New Strong Sell Stocks for April 26th
Amphastar Pharmaceuticals (AMPH) Stock Moves -1%: What You Should Know
Other News for AMPH
Federal Trade Commission Targets 'Junk Patent Listings' For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca
Novo, Teva, AstraZeneca issued FTC warnings over ‘bogus’ patents
FTC expands patent listing challenges for drugs
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 8, 2024
Amphastar Pharmaceuticals Poised for Growth: Strong Generic Pipeline and Strategic Marketing Drive Buy Rating